Exelixis (EXEL) Long-Term Investments (2010 - 2026)
Exelixis (EXEL) posted quarterly Long-Term Investments of $649.1 million for Q2 2026, up 4.8% year-over-year from $619.4 million in Q2 2025, and up 7.54% quarter-over-quarter from $603.6 million in Q1 2026.
Analysis
Exelixis (EXEL) Long-Term Investments (2010 - 2026) Analysis & Trends
Exelixis' Long-Term Investments history runs 17 years deep, the most recent figure standing at $649.1 million for Q2 2026.
- In Q2 2026, Long-Term Investments rose 4.8% year-over-year to $649.1 million; the TTM figure through Apr 2026 stood at $649.1 million (up 4.8% YoY), while the FY2026 annual figure was $603.6 million, down 5.29% from the prior year.
- Long-Term Investments for Q2 2026 stood at $649.1 million, up from $603.6 million in the prior quarter.
- The five-year high for Long-Term Investments was $838.6 million in Q2 2023, with the low at $404.5 million in Q2 2022.
- The 5-year median for Long-Term Investments is $619.4 million (2025), against an average of $625.3 million.
- The sharpest annual moves came in 2022 and 2024: Long-Term Investments soared 103.91% in 2022, then tumbled 48.45% in 2024.
- Exelixis' Long-Term Investments stood at $756.7 million in 2022, then decreased by 3.7% to $728.7 million in 2023, then slipped by 28.17% to $523.4 million in 2024, then grew by 10.48% to $578.3 million in 2025, then advanced by 12.25% to $649.1 million in 2026.
- Business Quant data shows EXEL's Long-Term Investments at $649.1 million in Q2 2026, $603.6 million in Q1 2026, and $578.3 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -4.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 1.77 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 372.10 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 544.93 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 544.93 Mn |
| Apr 3, 2026 | 649.14 Mn |
| Jan 2, 2026 | 603.60 Mn |
| Oct 3, 2025 | 578.29 Mn |
| Jul 4, 2025 | 594.65 Mn |
| Apr 4, 2025 | 619.44 Mn |
| Jan 3, 2025 | 637.29 Mn |
| Sep 27, 2024 | 523.42 Mn |
| Jun 28, 2024 | 432.31 Mn |
| Mar 29, 2024 | 629.56 Mn |
| Dec 29, 2023 | 728.72 Mn |
| Sep 29, 2023 | 811.68 Mn |
| Jun 30, 2023 | 838.62 Mn |
| Mar 31, 2023 | 806.62 Mn |
| Dec 30, 2022 | 756.73 Mn |
| Sep 30, 2022 | 551.74 Mn |
| Jul 1, 2022 | 463.89 Mn |
| Apr 1, 2022 | 404.54 Mn |
| Dec 31, 2021 | 371.11 Mn |
| Oct 1, 2021 | 362.22 Mn |